AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 83 min read$CRSP

Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics (CRSP) shares rose 19% in August following its Q2 earnings report. Sales of its blood disorder treatment Casgevy increased 78% to $76M, and the FDA expanded its approval. Revenue reached $10.2M, up from $892K a year ago, with a net loss of $91.5M. Analysts expected lower revenue and a larger loss. The company is developing treatments for hypertension and other disorders.

Original reporting
yahoo.com
Published Sep 8, 2026, 10:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 10:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Why CRISPR Therapeutics Stock Rocked the Market Last Month — source image
Source · yahoo.com
Decision brief

The 30-second read

$CRSPBullishMed
01

Why it matters

Earnings beat and regulatory news may trigger a short‑term rally, but long‑term valuation depends on pipeline execution.

02

Market read

First‑hand earnings and FDA news provide fresh material for traders targeting biotech momentum.

03

What to watch

Unidentified $10M upfront payment source and future partnership pipeline.

Relevance 8/10Novelty 8/10Timing: early August (Q2 release)

Background

CRISPR Therapeutics reported Q2 results and FDA label expansion for its approved product Casgevy.

Company-level read

Ticker impact

$CRSPBullishHigh confidence
Context

Q2 earnings released Aug 3 with revenue $10.2M, net loss $91.5M and FDA label expansion for Casgevy.

Expected impact

upward pressure in pre‑market trading

Evidence & confidence

Revenue topped analyst forecasts and a new pediatric indication adds growth potential.

Market effects

Sector

Strengthens outlook for gene‑editing biotech sector.

Regional

Positive for US biotech investors.

Global

Highlights FDA's expanding role in gene‑therapy approvals.

Counterpoint

What could challenge this read

Revenue still modest; loss remains high, risk of cash burn persists.

Key entities

  • company
    CRISPR Therapeutics

    Gene‑editing biotech (NASDAQ: CRSP).

  • partner
    Vertex Pharmaceuticals

    Co‑developer and marketer of Casgevy.

Read at source← All news

Related articles

OCT 2
$CRSPMedAI 8/10

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

CRISPR Therapeutics (CRSP) will present Phase 1 clinical data on its gene-edited CAR T cell therapy, zugocabtagene geleucel (zugo-cel), for autoimmune diseases at the ACR Convergence 2026. The presentation focuses on the therapy's safety and efficacy in treating refractory systemic sclerosis. CRISPR Therapeutics is a biopharmaceutical company developing gene-based medicines, with a pipeline spanning various diseases.

globenewswire.com1 min
SEP 26
$SNOWMed

Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock

Insiders at Snowflake (SNOW), Palo Alto (PANW), Dell (DELL), GameStop (GME), and Crispr (CRSP) made notable trades. SNOW's CRO sold $253,951 in shares, PANW's director sold $7.5M, DELL saw multiple sales totaling $22.9M, GME's CEO bought $26.4M in shares, and CRSP's shareholder sold $780,934. These transactions may signal insider expectations.

tipranks.com2 min
SEP 23
$CRSPMed

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.

newsable.asianetnews.com2 min
SEP 8
$CRSPMedAI 8/10

Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (CRSP) reported $76M in Q2 2026 revenue from Casgevy, up 78% sequentially and 151% YoY. The company has a strong pipeline, including CTX310 for cardiovascular disease and Zugo-cel for autoimmune diseases. With $2.36B in cash and a $5.4B market cap, CRISPR has financial flexibility to advance multiple programs. Success in these areas could significantly increase its valuation by 2031, though risks remain.

yahoo.com3 min
AUG 30
$CRSPMedAI 8/10

CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data

CRISPR Therapeutics (CRSP) stock is down 52.7% over 5 years, despite recent gains. The company presented Phase 1a data for CTX310, which may boost confidence in its drug pipeline. However, the stock is considered overvalued on market multiples, trading at a P/B of 3.2x, above the biotech industry average. Investors are paying a premium for its pipeline potential, but clinical and regulatory risks remain significant.

simplywall.st3 min